Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters.
Identifieur interne : 002357 ( PubMed/Curation ); précédent : 002356; suivant : 002358Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters.
Auteurs : Anjeanette Roberts [États-Unis] ; William D. Thomas ; Jeannette Guarner ; Elaine W. Lamirande ; Gregory J. Babcock ; Thomas C. Greenough ; Leatrice Vogel ; Norman Hayes ; John L. Sullivan ; Sherif Zaki ; Kanta Subbarao ; Donna M. AmbrosinoSource :
- The Journal of infectious diseases [ 0022-1899 ] ; 2006.
Descripteurs français
- KwdFr :
- Animaux, Anticorps antiviraux (administration et posologie), Anticorps antiviraux (sang), Anticorps antiviraux (usage thérapeutique), Anticorps monoclonaux (administration et posologie), Anticorps monoclonaux (usage thérapeutique), Charge virale, Cricetinae, Femelle, Immunoglobuline G (sang), Immunothérapie, Mesocricetus, Modèles animaux de maladie humaine, Pneumopathies interstitielles (anatomopathologie), Poumon (anatomopathologie), Poumon (virologie), Syndrome respiratoire aigu sévère (), Syndrome respiratoire aigu sévère (physiopathologie), Syndrome respiratoire aigu sévère (virologie), Tests de neutralisation, Virus du SRAS (immunologie), Virus du SRAS (physiologie).
- MESH :
- administration et posologie : Anticorps antiviraux, Anticorps monoclonaux.
- anatomopathologie : Pneumopathies interstitielles, Poumon.
- immunologie : Virus du SRAS.
- physiologie : Virus du SRAS.
- physiopathologie : Syndrome respiratoire aigu sévère.
- sang : Anticorps antiviraux, Immunoglobuline G.
- usage thérapeutique : Anticorps antiviraux, Anticorps monoclonaux.
- virologie : Poumon, Syndrome respiratoire aigu sévère.
- Animaux, Charge virale, Cricetinae, Femelle, Immunothérapie, Mesocricetus, Modèles animaux de maladie humaine, Syndrome respiratoire aigu sévère, Tests de neutralisation.
English descriptors
- KwdEn :
- Animals, Antibodies, Monoclonal (administration & dosage), Antibodies, Monoclonal (therapeutic use), Antibodies, Viral (administration & dosage), Antibodies, Viral (blood), Antibodies, Viral (therapeutic use), Cricetinae, Disease Models, Animal, Female, Immunoglobulin G (blood), Immunotherapy, Lung (pathology), Lung (virology), Lung Diseases, Interstitial (pathology), Mesocricetus, Neutralization Tests, SARS Virus (immunology), SARS Virus (physiology), Severe Acute Respiratory Syndrome (physiopathology), Severe Acute Respiratory Syndrome (therapy), Severe Acute Respiratory Syndrome (virology), Viral Load.
- MESH :
- chemical , administration & dosage : Antibodies, Monoclonal, Antibodies, Viral.
- chemical , blood : Antibodies, Viral, Immunoglobulin G.
- chemical , therapeutic use : Antibodies, Monoclonal, Antibodies, Viral.
- immunology : SARS Virus.
- pathology : Lung, Lung Diseases, Interstitial.
- physiology : SARS Virus.
- physiopathology : Severe Acute Respiratory Syndrome.
- therapy : Severe Acute Respiratory Syndrome.
- virology : Lung, Severe Acute Respiratory Syndrome.
- Animals, Cricetinae, Disease Models, Animal, Female, Immunotherapy, Mesocricetus, Neutralization Tests, Viral Load.
Abstract
Immunotherapy with monoclonal antibodies (MAbs) offers safe interventions for the prevention of infection in patients after organ transplantation and for the treatment of cancers and autoimmune diseases. MAb 201 is a severe acute respiratory syndrome-associated coronavirus (SARS-CoV)-specific MAb that prevents establishment of viral replication in vitro and prevents viral replication in vivo when administered prophylactically. The efficacy of MAb 201 in the treatment of SARS was evaluated in golden Syrian hamsters, an animal model that supports SARS-CoV replication to high levels and displays severe pathological changes associated with infection, including pneumonitis and pulmonary consolidation.
DOI: 10.1086/500143
PubMed: 16453264
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002357
Links to Exploration step
pubmed:16453264Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters.</title><author><name sortKey="Roberts, Anjeanette" sort="Roberts, Anjeanette" uniqKey="Roberts A" first="Anjeanette" last="Roberts">Anjeanette Roberts</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland</wicri:regionArea></affiliation></author><author><name sortKey="Thomas, William D" sort="Thomas, William D" uniqKey="Thomas W" first="William D" last="Thomas">William D. Thomas</name></author><author><name sortKey="Guarner, Jeannette" sort="Guarner, Jeannette" uniqKey="Guarner J" first="Jeannette" last="Guarner">Jeannette Guarner</name></author><author><name sortKey="Lamirande, Elaine W" sort="Lamirande, Elaine W" uniqKey="Lamirande E" first="Elaine W" last="Lamirande">Elaine W. Lamirande</name></author><author><name sortKey="Babcock, Gregory J" sort="Babcock, Gregory J" uniqKey="Babcock G" first="Gregory J" last="Babcock">Gregory J. Babcock</name></author><author><name sortKey="Greenough, Thomas C" sort="Greenough, Thomas C" uniqKey="Greenough T" first="Thomas C" last="Greenough">Thomas C. Greenough</name></author><author><name sortKey="Vogel, Leatrice" sort="Vogel, Leatrice" uniqKey="Vogel L" first="Leatrice" last="Vogel">Leatrice Vogel</name></author><author><name sortKey="Hayes, Norman" sort="Hayes, Norman" uniqKey="Hayes N" first="Norman" last="Hayes">Norman Hayes</name></author><author><name sortKey="Sullivan, John L" sort="Sullivan, John L" uniqKey="Sullivan J" first="John L" last="Sullivan">John L. Sullivan</name></author><author><name sortKey="Zaki, Sherif" sort="Zaki, Sherif" uniqKey="Zaki S" first="Sherif" last="Zaki">Sherif Zaki</name></author><author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name></author><author><name sortKey="Ambrosino, Donna M" sort="Ambrosino, Donna M" uniqKey="Ambrosino D" first="Donna M" last="Ambrosino">Donna M. Ambrosino</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="RBID">pubmed:16453264</idno><idno type="pmid">16453264</idno><idno type="doi">10.1086/500143</idno><idno type="wicri:Area/PubMed/Corpus">002357</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002357</idno><idno type="wicri:Area/PubMed/Curation">002357</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002357</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters.</title><author><name sortKey="Roberts, Anjeanette" sort="Roberts, Anjeanette" uniqKey="Roberts A" first="Anjeanette" last="Roberts">Anjeanette Roberts</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland</wicri:regionArea></affiliation></author><author><name sortKey="Thomas, William D" sort="Thomas, William D" uniqKey="Thomas W" first="William D" last="Thomas">William D. Thomas</name></author><author><name sortKey="Guarner, Jeannette" sort="Guarner, Jeannette" uniqKey="Guarner J" first="Jeannette" last="Guarner">Jeannette Guarner</name></author><author><name sortKey="Lamirande, Elaine W" sort="Lamirande, Elaine W" uniqKey="Lamirande E" first="Elaine W" last="Lamirande">Elaine W. Lamirande</name></author><author><name sortKey="Babcock, Gregory J" sort="Babcock, Gregory J" uniqKey="Babcock G" first="Gregory J" last="Babcock">Gregory J. Babcock</name></author><author><name sortKey="Greenough, Thomas C" sort="Greenough, Thomas C" uniqKey="Greenough T" first="Thomas C" last="Greenough">Thomas C. Greenough</name></author><author><name sortKey="Vogel, Leatrice" sort="Vogel, Leatrice" uniqKey="Vogel L" first="Leatrice" last="Vogel">Leatrice Vogel</name></author><author><name sortKey="Hayes, Norman" sort="Hayes, Norman" uniqKey="Hayes N" first="Norman" last="Hayes">Norman Hayes</name></author><author><name sortKey="Sullivan, John L" sort="Sullivan, John L" uniqKey="Sullivan J" first="John L" last="Sullivan">John L. Sullivan</name></author><author><name sortKey="Zaki, Sherif" sort="Zaki, Sherif" uniqKey="Zaki S" first="Sherif" last="Zaki">Sherif Zaki</name></author><author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name></author><author><name sortKey="Ambrosino, Donna M" sort="Ambrosino, Donna M" uniqKey="Ambrosino D" first="Donna M" last="Ambrosino">Donna M. Ambrosino</name></author></analytic><series><title level="j">The Journal of infectious diseases</title><idno type="ISSN">0022-1899</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies, Monoclonal (administration & dosage)</term><term>Antibodies, Monoclonal (therapeutic use)</term><term>Antibodies, Viral (administration & dosage)</term><term>Antibodies, Viral (blood)</term><term>Antibodies, Viral (therapeutic use)</term><term>Cricetinae</term><term>Disease Models, Animal</term><term>Female</term><term>Immunoglobulin G (blood)</term><term>Immunotherapy</term><term>Lung (pathology)</term><term>Lung (virology)</term><term>Lung Diseases, Interstitial (pathology)</term><term>Mesocricetus</term><term>Neutralization Tests</term><term>SARS Virus (immunology)</term><term>SARS Virus (physiology)</term><term>Severe Acute Respiratory Syndrome (physiopathology)</term><term>Severe Acute Respiratory Syndrome (therapy)</term><term>Severe Acute Respiratory Syndrome (virology)</term><term>Viral Load</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Anticorps antiviraux (administration et posologie)</term><term>Anticorps antiviraux (sang)</term><term>Anticorps antiviraux (usage thérapeutique)</term><term>Anticorps monoclonaux (administration et posologie)</term><term>Anticorps monoclonaux (usage thérapeutique)</term><term>Charge virale</term><term>Cricetinae</term><term>Femelle</term><term>Immunoglobuline G (sang)</term><term>Immunothérapie</term><term>Mesocricetus</term><term>Modèles animaux de maladie humaine</term><term>Pneumopathies interstitielles (anatomopathologie)</term><term>Poumon (anatomopathologie)</term><term>Poumon (virologie)</term><term>Syndrome respiratoire aigu sévère ()</term><term>Syndrome respiratoire aigu sévère (physiopathologie)</term><term>Syndrome respiratoire aigu sévère (virologie)</term><term>Tests de neutralisation</term><term>Virus du SRAS (immunologie)</term><term>Virus du SRAS (physiologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term><term>Immunoglobulin G</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Anticorps antiviraux</term><term>Anticorps monoclonaux</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Pneumopathies interstitielles</term><term>Poumon</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Lung</term><term>Lung Diseases, Interstitial</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term><term>Immunoglobuline G</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps antiviraux</term><term>Anticorps monoclonaux</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Poumon</term><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Lung</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Cricetinae</term><term>Disease Models, Animal</term><term>Female</term><term>Immunotherapy</term><term>Mesocricetus</term><term>Neutralization Tests</term><term>Viral Load</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Charge virale</term><term>Cricetinae</term><term>Femelle</term><term>Immunothérapie</term><term>Mesocricetus</term><term>Modèles animaux de maladie humaine</term><term>Syndrome respiratoire aigu sévère</term><term>Tests de neutralisation</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Immunotherapy with monoclonal antibodies (MAbs) offers safe interventions for the prevention of infection in patients after organ transplantation and for the treatment of cancers and autoimmune diseases. MAb 201 is a severe acute respiratory syndrome-associated coronavirus (SARS-CoV)-specific MAb that prevents establishment of viral replication in vitro and prevents viral replication in vivo when administered prophylactically. The efficacy of MAb 201 in the treatment of SARS was evaluated in golden Syrian hamsters, an animal model that supports SARS-CoV replication to high levels and displays severe pathological changes associated with infection, including pneumonitis and pulmonary consolidation.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16453264</PMID><DateCompleted><Year>2006</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0022-1899</ISSN><JournalIssue CitedMedium="Print"><Volume>193</Volume><Issue>5</Issue><PubDate><Year>2006</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>The Journal of infectious diseases</Title><ISOAbbreviation>J. Infect. Dis.</ISOAbbreviation></Journal><ArticleTitle>Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters.</ArticleTitle><Pagination><MedlinePgn>685-92</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Immunotherapy with monoclonal antibodies (MAbs) offers safe interventions for the prevention of infection in patients after organ transplantation and for the treatment of cancers and autoimmune diseases. MAb 201 is a severe acute respiratory syndrome-associated coronavirus (SARS-CoV)-specific MAb that prevents establishment of viral replication in vitro and prevents viral replication in vivo when administered prophylactically. The efficacy of MAb 201 in the treatment of SARS was evaluated in golden Syrian hamsters, an animal model that supports SARS-CoV replication to high levels and displays severe pathological changes associated with infection, including pneumonitis and pulmonary consolidation.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Golden Syrian hamsters that were intranasally inoculated with SARS-CoV were treated with various doses of MAb 201 or an irrelevant MAb 24 h after inoculation. Two to 7 days after infection, the hamsters were killed, and their lungs were collected for evaluation of viral titers and pathological findings.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Postexposure treatment with MAb 201 can alleviate the viral burden and associated pathological findings in a golden Syrian hamster model of SARS-CoV infection. After a hamster is treated with MAb 201, its viral burden is reduced by 102.4-103.9 50% tissue-culture infectious doses per gram of tissue, and the severity of associated pathological findings, including interstitial pneumonitis and consolidation, is also remarkably reduced.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The demonstration of successful postexposure MAb 201 therapy in an animal model that demonstrates viral replication and associated pulmonary pathological findings suggests that MAb 201 may be useful in the arsenal of tools to combat SARS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Roberts</LastName><ForeName>Anjeanette</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>William D</ForeName><Initials>WD</Initials></Author><Author ValidYN="Y"><LastName>Guarner</LastName><ForeName>Jeannette</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Lamirande</LastName><ForeName>Elaine W</ForeName><Initials>EW</Initials></Author><Author ValidYN="Y"><LastName>Babcock</LastName><ForeName>Gregory J</ForeName><Initials>GJ</Initials></Author><Author ValidYN="Y"><LastName>Greenough</LastName><ForeName>Thomas C</ForeName><Initials>TC</Initials></Author><Author ValidYN="Y"><LastName>Vogel</LastName><ForeName>Leatrice</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Hayes</LastName><ForeName>Norman</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Sullivan</LastName><ForeName>John L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Zaki</LastName><ForeName>Sherif</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Subbarao</LastName><ForeName>Kanta</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Ambrosino</LastName><ForeName>Donna M</ForeName><Initials>DM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>N01AI65315</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01-AI65315</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>01</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Infect Dis</MedlineTA><NlmUniqueID>0413675</NlmUniqueID><ISSNLinking>0022-1899</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017563" MajorTopicYN="N">Lung Diseases, Interstitial</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008647" MajorTopicYN="N">Mesocricetus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>08</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>12</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>2</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>4</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>2</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16453264</ArticleId><ArticleId IdType="pii">JID34979</ArticleId><ArticleId IdType="doi">10.1086/500143</ArticleId><ArticleId IdType="pmc">PMC7109703</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Clin Pathol. 2004 Sep;57(9):912-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15333649</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2004 Jun 26;363(9427):2139-41</Citation><ArticleIdList><ArticleId IdType="pubmed">15220038</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect Dis. 1997 Nov;176(5):1215-24</Citation><ArticleIdList><ArticleId IdType="pubmed">9359721</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2003 May 24;361(9371):1767-72</Citation><ArticleIdList><ArticleId IdType="pubmed">12781535</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2005 May 2;23(24):3202-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15837221</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9804-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15210961</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect Dis. 2005 Feb 15;191(4):507-14</Citation><ArticleIdList><ArticleId IdType="pubmed">15655773</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 1990 Mar;64(3):1407-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2154621</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2005 Mar 18;23(17-18):2273-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15755610</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Med. 2004 Aug;10(8):871-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15247913</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2004 Apr;78(7):3572-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15016880</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 2003 May 15;423(6937):240</Citation><ArticleIdList><ArticleId IdType="pubmed">12748632</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2005 May;79(9):5833-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15827197</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 2004 Apr 1;428(6982):561-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15024391</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2005 Jan;79(1):503-11</Citation><ArticleIdList><ArticleId IdType="pubmed">15596843</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2004 Oct;78(20):11401-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15452262</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Am J Pathol. 2005 Aug;167(2):455-63</Citation><ArticleIdList><ArticleId IdType="pubmed">16049331</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Am J Vet Res. 1983 Feb;44(2):229-34</Citation><ArticleIdList><ArticleId IdType="pubmed">6299143</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2004 Jun 26;363(9427):2122-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15220033</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Am J Med Sci. 2002 Jul;324(1):14-30</Citation><ArticleIdList><ArticleId IdType="pubmed">12120821</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6641-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15096611</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 2005 Apr 10;334(2):160-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15780866</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Curr Opin Mol Ther. 2002 Apr;4(2):110-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12044031</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 2003 Oct 30;425(6961):915</Citation><ArticleIdList><ArticleId IdType="pubmed">14586458</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2005 May;79(10):5900-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15857975</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Pediatrics. 1998 Sep;102(3 Pt 1):531-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9738173</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 2004 Dec 5;330(1):8-15</Citation><ArticleIdList><ArticleId IdType="pubmed">15527829</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Med. 2004 Mar;10(3):290-3</Citation><ArticleIdList><ArticleId IdType="pubmed">14981511</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Med. 2004 Dec;10(12 Suppl):S88-97</Citation><ArticleIdList><ArticleId IdType="pubmed">15577937</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Clin Infect Dis. 2004 Oct 1;39(7):1071-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15472864</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002357 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002357 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:16453264
|texte= Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:16453264" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |